Disclaimer: This website is not affiliated with CytoDyn Inc.
August 11, 2020
CytoDyn Announces Top-line Efficacy Results:
Leronlimab Improved NEWS2 by 50%
Patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group.
Leronlimab Reduced Severe Adverse Effects
"39% (11 SAEs in 28 Patients) in Placebo Arm as Compared to Only 14% (8 SAEs in 56 Patients) in Leronlimab Arm Reported Serious Adverse Events (SAEs), Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will Be Announced Along With a Full Report as Soon as Statistical Analyses Are Completed"
Recent News Coverage:
CytoDyn touts ‘impressive’ early results for virus drug: Biotech company’s Leronlimab may aid in symptom control:
Scientists are making headway in the hunt for COVID-19 treatments and vaccines and North Texans are being asked to be a part of it:
Video supplement: https://youtu.be/sJAdnCROf2U
OC Woman Credits Experimental Antibody Drug for COVID-19
Cork woman raising money for friend diagnosed with aggressive breast cancer
CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study
Vancouver-based CytoDyn expects COVID-19 trial results this month
Yale infectious disease doctor weighs in on HIV drug’s promise for Covid-19 and mask safety
For some with COVID-19, symptoms can linger for weeks, even months
CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH